전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved665 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#LungCancerStageIII+1
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Cromolyn, TQB2102, and Panpulimab (Cromolyn, TQB2102, and Panpulimab)

Triple -Negative Breast Cancer · Triple -Negative Breast Cancer

#Triple-NegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Cryoablation Combined with Tirelizumab and Bevacizumab (Cryoablation Combined with Tirelizumab and Bevacizumab)

Metastatic Breast Cancer in the Liver · Metastatic Breast Cancer in the Liver

#MetastaticBreastCancerintheLiver#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleKahr Bio Australia Pty LtdPhase 2

atezolizumab (Tecentriq, DSP107 + Atezolizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#Kahr
Trials 1Status Recruiting
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Fruquintinib)

HER2; Colorectal Cancer · HER2

#HER2#ADC#Approved#antibody-drug-conjugate#ColorectalCancer+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin plus pyrotinib or naratinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin（RC48-ADC）)

Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital w…Phase 2

Disitamb Vedotin ,pyrotinib (Disitamb Vedotin ,pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
AntibodyLimited DatastaleSanofiPhase 2

Docetaxel (Docetaxel, Docetaxel (T) + bevacizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Active
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
CGTLimited DatastaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleQilu Hospital of Shandong Unive…Preclinical

Doublet or triplet chemotherapy combined with cetuximab (Doublet or triplet chemotherapy combined with cetuximab)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Preclinical#monoclonal-antibody#Qilu
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleKyoto Breast Cancer Research Ne…Phase 2

Durvalmab&Tremelimumab&Fulvestrant (Durvalmab&Tremelimumab&Fulvestrant)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Kyoto
Trials 1Status Discontinued

18 / 34 pages

← PreviousNext →